, Tracking Stock Market Picks
Enter Symbol:

Mkt Outperform
up 68.75 %

REXAHN PHARMACEUTICL (RNN) rated Mkt Outperform with price target $1 by Burrill Institutional Research

Posted on: Friday,  Dec 28, 2012  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform REXAHN PHARMACEUTICL (AMEX: RNN) on 12/28/2012, when the stock price was $0.32.
Since then, REXAHN PHARMACEUTICL has gained 68.75% as of 08/27/2015's recent price of $0.54.
If you would have followed this Burrill Institutional Research's recommendation on RNN, you would have gained 68.75% of your investment in 972 days.

Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in Phase II clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development. The Company?s clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant and CNS Disorders drug, and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. Rexahn?s pre-clinical pipeline includes RX-0201-Nano, RX-0047-Nano, Nano-polymer Anticancer Drugs, RX-0183, RX-5902 and RX-3117.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/28/2012 8:25 AM Buy
0.32 1.00
as of 12/31/2012
1 Week down  -3.12 %
1 Month   
3 Months   
1 YTD down  -3.12 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy